共查询到20条相似文献,搜索用时 31 毫秒
1.
Alonso G Ambrosino C Jones M Nebreda AR 《The Journal of biological chemistry》2000,275(51):40641-40648
We have investigated the ability of the mitogen-activated protein kinase (MAPK) kinase MKK6 to activate different members of the p38 subfamily of MAPKs and found that some MKK6 mutants can efficiently activate p38alpha but not p38gamma. In contrast, a constitutively active MKK6 mutant activated both p38 MAPK isoforms to similar extents. The same results were obtained upon co-expression in Xenopus oocytes and in vitro using either MKK6 immunoprecipitates from transfected cells or bacterially produced recombinant proteins. We also found that the preferential activation of p38alpha by MKK6 correlated with more efficient binding of MKK6 to p38alpha than to p38gamma. Furthermore, increasing concentrations of constitutively active MKK6 differentially activated either p38alpha alone (low MKK6 activity) or both p38alpha and p38gamma (high MKK6 activity), both in vitro and in injected oocytes. The determinants for selectivity are located at the carboxyl-terminal lobe of p38 MAPKs but do not correspond to the activation loop or common docking sequences. We also showed that different stimuli can induce different levels of endogenous MKK6 activity that correlate with differential activation of p38 MAPKs. Our results suggest that the level of MKK6 activity triggered by a given stimulus may determine the pattern of downstream p38 MAPK activation in the particular response. 相似文献
2.
Lenka Munoz Roland Selig Christian Peifer Stefan Laufer 《Analytical biochemistry》2010,401(1):125-133
Development of inhibitors that target inactive kinase conformations is becoming a more attractive approach to kinase inhibitor research. The major advantage of this methodology is that targeting the inactive conformation reduces competition with high intracellular adenosine triphosphate (ATP) concentrations. p38α Mitogen-activated protein kinase (MAPK) signaling has been identified as the principal mediator of inflammation associated with a spectrum of disorders (e.g., arthritis, Alzheimer’s disease, various malignancies). To allow identification and development of p38α MAPK inhibitors that preferentially bind to the inactive conformation, a novel fluorescence polarization-based binding assay is presented. The assay is homogeneous, requires low amounts of the kinase and fluoroprobe, and does not rely on radioactivity. It may, therefore, offer an inexpensive alternative to current p38α MAPK inhibitor screening methods. The validation of the system with known p38α MAPK inhibitors confirmed that the binding assay, rather than the conventional enzyme activity assay, correlates with cellular efficacy. Finally, we show that pyridinyl imidazoles that potently bind to the inactive p38α MAPK prevent activation of p38 MAPK in living cells, suggesting that pyridinyl imidazoles other than SB203580 are able to induce the DFG-out conformation that is incompatible with activation (where DFG is a single-letter amino acid code for the aspartate-phenylalanine-glycine sequence at the start of the activation loop). 相似文献
3.
Hu Liu Cyrille Kuhn Frederic Feru Suzanne L. Jacques Gayatri D. Deshmukh Ping Ye Glen R. Rennie Theresa Johnson Steven Kazmirski Simon Low Rocco Coli Yuan-hua Ding Alan C. Cheng Haile Tecle Jessie M. English Robert Stanton Joe C. Wu 《Bioorganic & medicinal chemistry letters》2010,20(16):4885-4891
By targeting an extended region of the conventional ‘DFG-out’ pocket of p38α, while minimizing interactions with the specificity pocket and eliminating interactions with the adenine binding site, we are able to design and synthesize a number of pyrazole-urea based DFG-out p38α inhibitors with good potencies, and excellent selectivity. 相似文献
4.
Andreas Kuglstatter Manjiri Ghate Stan Tsing Armando G. Villaseñor David Shaw Jim W. Barnett Michelle F. Browner 《Bioorganic & medicinal chemistry letters》2010,20(17):5217-5220
JNK2 and p38α are closely related mitogen-activated protein kinases that regulate various cellular activities and are considered drug targets for inflammatory diseases. We have determined the X-ray crystal structure of the clinical phase II p38α inhibitor BIRB796 bound to its off-target JNK2. This shows for the first time a JNK subfamily member in the DFG-out conformation. The fully resolved activation loop reveals that BIRB796 inhibits JNK2 activation by stabilizing the loop in a position that does not allow its phosphorylation by upstream kinases. The structure suggests that substituents at the BIRB796 morpholino group and modifications of the t-butyl moiety should further increase the p38α to JNK2 potency ratio. For the design of selective DFG-out binding JNK2 inhibitors, the binding pocket of the BIRB796 tolyl group may have the best potential. 相似文献
5.
Dmitry Suplatov Kirill Kopylov Yana Sharapova 《Journal of biomolecular structure & dynamics》2019,37(8):2049-2060
Doramapimod (BIRB-796) is widely recognized as one of the most potent and selective type II inhibitors of human p38α mitogen-activated protein kinase (MAPK); however, the understanding of its binding mechanism remains incomplete. Previous studies indicated high affinity of the ligand to a so-called allosteric pocket revealed only in the ‘out’ state of the DFG motif (i.e. Asp168-Phe169-Gly170) when Phe169 becomes fully exposed to the solvent. The possibility of alternative binding in the DFG-in state was hypothesized, but the molecular mechanism was not known. Methods of bioinformatics, docking and long-time scale classical and accelerated molecular dynamics have been applied to study the interaction of Doramapimod with the human p38α MAPK. It was shown that Doramapimod can bind to the protein even when the Phe169 is fully buried inside the allosteric pocket and the kinase activation loop is in the DFG-in state. Orientation of the inhibitor in such a complex is significantly different from that in the known crystallographic complex formed by the kinase in the DFG-out state; however, the Doramapimod’s binding is followed by the ligand-induced conformational changes, which finally improve accommodation of the inhibitor. Molecular modelling has confirmed that Doramapimod combines the features of type I and II inhibitors of p38α MAPK, i.e. can directly and indirectly compete with the ATP binding. It can be concluded that optimization of the initial binding in the DFG-in state and the final accommodation in the DFG-out state should be both considered at designing novel efficient type II inhibitors of MAPK and homologous proteins.
Communicated by Ramaswamy H. Sarma 相似文献
6.
Unique MAP Kinase binding sites 总被引:1,自引:0,他引:1
Map kinases are drug targets for autoimmune disease, cancer, and apoptosis-related diseases. Drug discovery efforts have developed MAP kinase inhibitors directed toward the ATP binding site and neighboring "DFG-out" site, both of which are targets for inhibitors of other protein kinases. On the other hand, MAP kinases have unique substrate and small molecule binding sites that could serve as inhibition sites. The substrate and processing enzyme D-motif binding site is present in all MAP kinases, and has many features of a good small molecule binding site. Further, the MAP kinase p38alpha has a binding site near its C-terminus discovered in crystallographic studies. Finally, the MAP kinases ERK2 and p38alpha have a second substrate binding site, the FXFP binding site that is exposed in active ERK2 and the D-motif peptide induced conformation of MAP kinases. Crystallographic evidence of these latter two binding sites is presented. 相似文献
7.
8.
Parallel regulation of mitogen-activated protein kinase kinase 3 (MKK3) and MKK6 in Gq-signaling cascade 总被引:4,自引:0,他引:4
Yamauchi J Tsujimoto G Kaziro Y Itoh H 《The Journal of biological chemistry》2001,276(26):23362-23372
Heterotrimeric G protein G(q) stimulates the activity of p38 mitogen-activated protein kinase (MAPK) in mammalian cells. To investigate the signaling mechanism whereby alpha and betagamma subunits of G(q) activate p38 MAPK, we introduced kinase-deficient mutants of mitogen-activated protein kinase kinase 3 (MKK3), MKK4, and MKK6 into human embryonal kidney 293 cells. The activation of p38 MAPK by Galpha(q) and Gbetagamma was blocked by kinase-deficient MKK3 and MKK6 but not by kinase-deficient MKK4. In addition, Galpha(q) and Gbetagamma stimulated MKK3 and MKK6 activities. The MKK3 and MKK6 activations by Galpha(q), but not by Gbetagamma, were dependent on phospholipase C and c-Src. Galpha(q) stimulated MKK3 in a Rac- and Cdc42-dependent manner and MKK6 in a Rho-dependent manner. On the other hand, Gbetagamma activated MKK3 in a Rac- and Cdc42-dependent manner and MKK6 in a Rho-, Rac-, and Cdc42-dependent manner. Gbetagamma-induced MKK3 and MKK6 activations were dependent on a tyrosine kinase other than c-Src. These results suggest that Galpha(q) and Gbetagamma stimulate the activity of p38 MAPK by regulating MKK3 and MKK6 through parallel signaling pathways. 相似文献
9.
Kaur R Liu X Gjoerup O Zhang A Yuan X Balk SP Schneider MC Lu ML 《The Journal of biological chemistry》2005,280(5):3323-3330
The p21-activated kinases (PAKs) contain an N-terminal Cdc42/Rac interactive binding domain, which in the group 1 PAKs (PAK1, 2, and 3) regulates the activity of an adjacent conserved autoinhibitory domain. In contrast, the group 2 PAKs (PAK4, 5, and 6) lack this autoinhibitory domain and are not activated by Cdc42/Rac binding, and the mechanisms that regulate their kinase activity have been unclear. This study found that basal PAK6 kinase activity was repressed by a p38 mitogen-activated protein (MAP) kinase antagonist and could be strongly stimulated by constitutively active MAP kinase kinase 6 (MKK6), an upstream activator of p38 MAP kinases. Mutation of a consensus p38 MAP kinase target site at serine 165 decreased PAK6 kinase activity. Moreover, PAK6 was directly activated by MKK6, and mutation of tyrosine 566 in a consensus MKK6 site (threonine-proline-tyrosine, TPY) in the activation loop of the PAK6 kinase domain prevented activation by MKK6. PAK6 activation by MKK6 was also blocked by mutation of an autophosphorylated serine (serine 560) in the PAK6 activation loop, indicating that phosphorylation of this site is necessary for MKK6-mediated activation. PAK4 and PAK5 were similarly activated by MKK6, consistent with a conserved TPY motif in their activation domains. The activation of PAK6 by both p38 MAP kinase and MKK6 suggests that PAK6 plays a role in the cellular response to stress-related signals. 相似文献
10.
The p38alpha MAPK participates in a variety of biological processes. Activation of p38alpha is mediated by phosphorylation on specific regulatory tyrosine and threonine sites, and the three dual kinases, MAPK kinase 3 (MKK3), MKK4, and MKK6, are known to be the upstream activators of p38alpha. In addition to activation by upstream kinases, p38alpha can autoactivate when interacting with transforming growth factor-beta-activated protein kinase 1-binding protein 1 (TAB1). Here we used MKK3 and MKK6 double knock-out (MKK3/6 DKO) and MKK4/7 DKO mouse embryonic fibroblast (MEF) cells to examine activation mechanisms of p38alpha. We confirmed that the MKK3/6 pathway is a primary mechanism for p38alpha phosphorylation in MEF cells, and we also showed the presence of other p38alpha activation pathways. We show that TAB1-mediated p38alpha phosphorylation in MEF cells did not need MKK3/4/6, and it accounted for a small portion of the total p38alpha phosphorylation that was induced by hyperosmolarity and anisomycin. We observed that a portion of peroxynitrite-induced phospho-p38alpha is associated with an approximately 85-kDa disulfide complex in wild-type MEF cells. Peroxynitrite-induced phosphorylation of p38alpha in the approximately 85-kDa complex is independent from MKK3/6 because only phospho-p38alpha not associated with the disulfide complex was diminished in MKK3/6 DKO cells. In addition, our data suggest interference among different pathways because TAB1 had an inhibitory effect on p38alpha phosphorylation in the peroxynitrite-induced approximately 85-kDa complex. Mutagenesis analysis of the cysteines in p38alpha revealed that no disulfide bond forms between p38alpha and other proteins in the approximately 85-kDa complex, suggesting it is a p38alpha binding partner(s) that forms disulfide bonds, which enable it to bind to p38alpha. Therefore, multiple mechanisms of p38alpha activation exist that can influence each other, be simultaneously activated by a given stimulus, and/or be selectively used by different stimuli in a cell type-specific manner. 相似文献
11.
Gills JJ Castillo SS Zhang C Petukhov PA Memmott RM Hollingshead M Warfel N Han J Kozikowski AP Dennis PA 《The Journal of biological chemistry》2007,282(37):27020-27029
Previously, we identified five active phosphatidylinositol ether lipid analogues (PIAs) that target the pleckstrin homology domain of Akt and selectively induce apoptosis in cancer cells with high levels of Akt activity. To examine specificity, PIAs were screened against a panel of 29 purified kinases. No kinase was inhibited, but one isoform of p38, p38alpha, was uniformly activated 2-fold. Molecular modeling of p38alpha revealed the presence of two regions that could interact with PIAs, one in the activation loop and a heretofore unappreciated region in the upper lobe that resembles a pleckstrin homology domain. In cells, two phases of activation were observed, an early phase that was independent of the upstream kinase MKK3/6 and inhibited by the p38 inhibitor SB203580 and a latter phase that was coincident with MKK3/6 activation. In short term xenograft experiments that employed immunohistochemistry and immunoblotting, PIA administration increased phosphorylation of p38 but not MKK3/6 in tumors in a statistically significant manner. Although PIAs rapidly activated p38 with similar time and dose dependence as Akt inhibition, p38 activation and Akt inhibition were independent events induced by PIAs. Using SB203580 or p38alpha(-/-) cells, we showed that p38alpha is not required for PIA-induced apoptosis but is required for H(2)O(2)- and anisomycin-induced apoptosis. Nonetheless, activation of p38a contributes to PIA-induced apoptosis, because reconstitution of p38a into p38alpha(-/-) cells increased apoptosis. These studies indicate that p38alpha is activated by PIAs through a novel mechanism and show that p38alpha activation contributes to PIA-induced cell death. Independent modulation of Akt and p38alpha could account for the profound cytotoxicity of PIAs. 相似文献
12.
Seungil Han Anil Mistry Jeanne S. Chang David Cunningham Matt Griffor Peter C. Bonnette Hong Wang Boris A. Chrunyk Gary E. Aspnes Daniel P. Walker Arthur D. Brosius Leonard Buckbinder 《The Journal of biological chemistry》2009,284(19):13193-13201
Proline-rich tyrosine kinase 2 (PYK2) is a cytoplasmic, non-receptor
tyrosine kinase implicated in multiple signaling pathways. It is a negative
regulator of osteogenesis and considered a viable drug target for osteoporosis
treatment. The high-resolution structures of the human PYK2 kinase domain with
different inhibitor complexes establish the conventional bilobal kinase
architecture and show the conformational variability of the DFG loop. The
basis for the lack of selectivity for the classical kinase inhibitor,
PF-431396, within the FAK family is explained by our structural analyses.
Importantly, the novel DFG-out conformation with two diarylurea inhibitors
(BIRB796, PF-4618433) reveals a distinct subclass of non-receptor tyrosine
kinases identifiable by the gatekeeper Met-502 and the unique hinge loop
conformation of Leu-504. This is the first example of a leucine residue in the
hinge loop that blocks the ATP binding site in the DFG-out conformation. Our
structural, biophysical, and pharmacological studies suggest that the unique
features of the DFG motif, including Leu-504 hinge-loop variability, can be
exploited for the development of selective protein kinase inhibitors.Proline-rich tyrosine kinase 2
(PYK2)2 and focal
adhesion kinase (FAK) comprise the focal adhesion kinase subfamily of
non-receptor tyrosine kinases. PYK2 and FAK are large multidomain proteins
containing an N-terminal FERM domain, a central catalytic domain, and a
C-terminal segment containing dual proline rich (PR) subdomains and a focal
adhesion targeting (FAT) region
(1,
2). While FAK is widely
expressed, PYK2 expression is relatively restricted with highest levels in
brain and the hematopoeitic system. Unlike FAK, optimal PYK2 activation is
dependent on Ca2+ mobilization. PYK2 (-/-) animals have been
described previously, and develop normally
(3,
4). Characterization of the
immune system of PYK2(-/-) animals revealed the absence of marginal zone
B-cells along with abnormal T-cell independent type II responses
(4), and altered macrophage
morphology, migration and signaling in response to cell attachment or
chemokine treatment (3). These
studies strengthen the link between PYK2 and signaling through chemokine and
integrin receptors. In addition, PYK2(-/-) mice were shown to have increased
susceptibility to diet-induced obesity and diabetes
(5).Recently, the characterization of PYK2(-/-) mice showed a high bone mass
phenotype resulting from increased osteogenesis and osteoblast activity. Using
PYK2(-/-) mouse bone marrow cultures and hMSCs expressing a PYK2 shRNA,
elimination or reduction of PYK2 protein levels resulted in significantly
enhanced osteogeogenesis. Importantly, the daily administration of a
pyrimidine-based PYK2 inhibitor, PF-431396, increased bone formation, and
protected against bone loss in ovariectomized rats
(6). PYK2(-/-) mice showed mild
osteopetrosis which was attributed to the impairment in osteoclast function
(7). Therefore, the high bone
mass phenotype may result from both enhanced osteoblast and impaired
osteoclast elements.PYK2 is one member of a family of over 500 evolutionarily conserved enzymes
with high amino acid and structural conservation within the catalytic ATP
binding pocket. Classical kinase inhibitors bind to the ATP site and compete
for substrate binding. Thus, while classical inhibitors based on ATP binding
analogs have been readily identified, the inherent promiscuity of action for
this class has presented significant challenges to drug design
(8). With the exception of
cancer therapeutics, where additional therapeutic benefits may be gained by
the inhibition of multiple kinase targets (e.g. Sutent, Sorafenib),
minimizing off-target activity is most often desired. Therefore, there is
great interest in identifying unique allosteric regulatory domains for
specific kinase targets. Despite intense effort, small molecule inhibitors
exploiting extra-catalytic allosteric sites have been limited to a few
examples including IKK (9) and
MEK (10). Alternatively,
bipartite inhibitors have been developed that stabilize an inactive
conformation of the protein kinase, the prototypical example being BIRB796
binding to p38 and Gleevec binding to Abl. Such compounds make contact with
both the conserved ATP site and less conserved regions of the activation loop,
thus offering the potential for improved selectivity
(11). The N terminus of the
activation loop contains an invariant Asp-Phe-Gly (DFG) motif, and is an
important determinant of enzyme activity. In the active or
“DFG-in” conformation, these amino acids are involved in the
coordination of ATP. Conversely, the “DFG-out” state does not bind
ATP and the kinase is inactive. While a handful of kinases are known to adopt
a DFG-out conformation (e.g. p38, Abl, etc), it remains to be
determined how general this strategy might be in the design of selective
kinase inhibitors.To help elucidate the molecular mechanism of PYK2 and its substrate
specificity, we used biophysical methods and determined multiple x-ray
structures of the PYK2 kinase domain. High-resolution structures of apo and
ATPγS-bound forms were obtained as well as a complex with PF-431396, a
“classical” kinase inhibitor. Empirical screening identified
BIRB796 as a weak PYK2 kinase inhibitor. Surface plasmon resonance (SPR) and
NMR studies indicated that PYK2 could adopt a “DFG-out”
conformation. Despite the low affinity, a 1.75-Å co-crystal structure
was obtained with BIRB796 revealing a novel binding mode. Our biophysical and
structural results provide insight into the enzyme-substrate complex and
allowed us to advance the rational design of a selective DFG-out inhibitor
with improved PYK2 selectivity and potency. The compound, PF-4618433, showed
robust osteogenic activity in hMSC cultures. 相似文献
13.
Justin Dietrich Christopher Hulme Laurence H. Hurley 《Bioorganic & medicinal chemistry》2010,18(15):5738-5748
The majority of kinase inhibitors developed to date are competitive inhibitors that target the ATP binding site; however, recent crystal structures of Gleevec® (imatinib mesylate, STI571, PDB: 1IEP), Nexavar® (Sorafenib tosylate, BAY 43-9006, PDB: 1UWJ), and BIRB-796 (PDB: 1KV2) have revealed a secondary binding site adjacent to the ATP binding site known as the DFG-out allosteric binding site. The recent successes of Gleevec® and Nexavar® for the treatment of chronic myeloid leukemia and renal cell carcinoma has generated great interest in the development of other kinase inhibitors that target this secondary binding site. Here, we present a structural comparison of the important and similar interactions necessary for Gleevec®, Nexavar®, and BIRB-796 to bind to their respective DFG-out allosteric binding pockets and the selectivity of each with respect to c-Abl, B-Raf, and p38α. A structural analysis of their selectivity profiles has been generated from the synthesis and evaluation of 8 additional DFG-out allosteric inhibitors that were developed directly from fragments of these successful scaffolds. 相似文献
14.
Gaëlle Remy Ana M. Risco Francisco A. Iñesta-Vaquera Bárbara González-Terán Guadalupe Sabio Roger J. Davis Ana Cuenda 《Cellular signalling》2010,22(4):660-667
All four members of the mammalian p38 mitogen-activated protein kinase (MAPK) family (p38α, p38β, p38γ and p38δ) are activated by dual phosphorylation in the TGY motif in the activation loop. This phosphorylation is mediated by three kinases, MKK3, MKK6 and MKK4, at least in vitro. The role of these MKK in the activation of p38α has been demonstrated in studies using fibroblasts that lack MKK3 and/or MKK6. Nonetheless, the physiological upstream activators of the other p38MAPK isoforms have not yet been reported using MKK knockout cells. In this study, we examined p38β, γ and δ activation by MKK3 and MKK6, in cells lacking MKK3, MKK6 or both. We show that MKK3 and MKK6 are both essential for the activation of p38γ and p38β induced by environmental stress, whereas MKK6 is the major p38γ activator in response to TNFα. In contrast, p38δ activation by ultraviolet radiation, hyperosmotic shock, anisomycin or by TNFα is mediated by MKK3. Moreover, in response to osmotic stress, MKK3 and MKK6 are crucial in regulating the phosphorylation of the p38γ substrate hDlg and its activity as scaffold protein. These data indicate that activation of distinct p38MAPK isoforms is regulated by the selective and synchronized action of two kinases, MKK3 and MKK6, in response to cell stress. 相似文献
15.
16.
Angell RM Angell TD Bamborough P Bamford MJ Chung CW Cockerill SG Flack SS Jones KL Laine DI Longstaff T Ludbrook S Pearson R Smith KJ Smee PA Somers DO Walker AL 《Bioorganic & medicinal chemistry letters》2008,18(15):4433-4437
The biphenyl amides (BPAs) are a series of p38α MAP kinase inhibitors. Compounds are able to bind to the kinase in either the DFG-in or DFG-out conformation, depending on substituents. X-ray, binding, kinetic and cellular data are shown, providing the most detailed comparison to date between potent compounds from the same chemical series that bind to different p38α conformations. DFG-out-binding compounds could be made more potent than DFG-in-binding compounds by increasing their size. Unexpectedly, compounds that bound to the DGF-out conformation showed diminished selectivity. The kinetics of binding to the isolated enzyme and the effects of compounds on cells were largely unaffected by the kinase conformation bound. 相似文献
17.
The majority of kinase inhibitors that have been developed so far--known as type I inhibitors--target the ATP binding site of the kinase in its active conformation, in which the activation loop is phosphorylated. Recently, crystal structures of inhibitors such as imatinib (STI571), BIRB796 and sorafenib (BAY43-9006)--known as type II inhibitors--have revealed a new binding mode that exploits an additional binding site immediately adjacent to the region occupied by ATP. This pocket is made accessible by an activation-loop rearrangement that is characteristic of kinases in an inactive conformation. Here, we present a structural analysis of binding modes of known human type II inhibitors and demonstrate that they conform to a pharmacophore model that is currently being used to design a new generation of kinase inhibitors. 相似文献
18.
Wrobleski ST Lin S Hynes J Wu H Pitt S Shen DR Zhang R Gillooly KM Shuster DJ McIntyre KW Doweyko AM Kish KF Tredup JA Duke GJ Sack JS McKinnon M Dodd J Barrish JC Schieven GL Leftheris K 《Bioorganic & medicinal chemistry letters》2008,18(8):2739-2744
A novel series of compounds based on the pyrrolo[2,1-f][1,2,4]triazine ring system have been identified as potent p38 alpha MAP kinase inhibitors. The synthesis, structure-activity relationships (SAR), and in vivo activity of selected analogs from this class of inhibitors are reported. Additional studies based on X-ray co-crystallography have revealed that one of the potent inhibitors from this series binds to the DFG-out conformation of the p38 alpha enzyme. 相似文献
19.
Kuglstatter A Wong A Tsing S Lee SW Lou Y Villaseñor AG Bradshaw JM Shaw D Barnett JW Browner MF 《Protein science : a publication of the Protein Society》2011,20(2):428-436
Bruton's tyrosine kinase (BTK) plays a key role in B cell receptor signaling and is considered a promising drug target for lymphoma and inflammatory diseases. We have determined the X-ray crystal structures of BTK kinase domain in complex with six inhibitors from distinct chemical classes. Five different BTK protein conformations are stabilized by the bound inhibitors, providing insights into the structural flexibility of the Gly-rich loop, helix C, the DFG sequence, and activation loop. The conformational changes occur independent of activation loop phosphorylation and do not correlate with the structurally unchanged WEI motif in the Src homology 2-kinase domain linker. Two novel activation loop conformations and an atypical DFG conformation are observed representing unique inactive states of BTK. Two regions within the activation loop are shown to structurally transform between 3(10)- and α-helices, one of which collapses into the adenosine-5'-triphosphate binding pocket. The first crystal structure of a Tec kinase family member in the pharmacologically important DFG-out conformation and bound to a type II kinase inhibitor is described. The different protein conformations observed provide insights into the structural flexibility of BTK, the molecular basis of its regulation, and the structure-based design of specific inhibitors. 相似文献
20.
ter Haar E Prabhakar P Prabakhar P Liu X Lepre C 《The Journal of biological chemistry》2007,282(13):9733-9739
The p38 signaling pathway is activated in response to cell stress and induces production of proinflammatory cytokines. P38alpha is phosphorylated and activated in response to cell stress by MKK3 and MKK6 and in turn phosphorylates a number of substrates, including MAPKAP kinase 2 (MK2). We have determined the crystal structure of the unphosphorylated p38alpha-MK2 heterodimer. The C-terminal regulatory domain of MK2 binds in the docking groove of p38alpha, and the ATP-binding sites of both kinases are at the heterodimer interface. The conformation suggests an extra mechanism in addition to the regulation of the p38alpha and MK2 phosphorylation states that prevents phosphorylation of substrates in the absence of cell stress. Addition of constitutively active MKK6-DD results in rapid phosphorylation of the p38alpha-MK2 heterodimer. 相似文献